| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer E Van Cutsem, CH Köhne, E Hitre, J Zaluski, CR Chang Chien, ... New England Journal of Medicine 360 (14), 1408-1417, 2009 | 4948 | 2009 |
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS … E Van Cutsem, CH Köhne, I Láng, G Folprecht, MP Nowacki, S Cascinu, ... Journal of Clinical Oncology 29 (15), 2011-2019, 2011 | 2364 | 2011 |
| Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced … SE Al-Batran, N Homann, C Pauligk, TO Goetze, J Meiler, S Kasper, ... The Lancet 393 (10184), 1948-1957, 2019 | 2216 | 2019 |
| Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial G Folprecht, T Gruenberger, WO Bechstein, HR Raab, F Lordick, ... The lancet oncology 11 (1), 38-47, 2010 | 1229 | 2010 |
| Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates G Folprecht, A Grothey, S Alberts, HR Raab, CH Köhne Annals of Oncology 16 (8), 1311-1319, 2005 | 844 | 2005 |
| Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of … C Rödel, T Liersch, H Becker, R Fietkau, W Hohenberger, T Hothorn, ... The lancet oncology 13 (7), 679-687, 2012 | 817 | 2012 |
| Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial T Ruers, F Van Coevorden, CJA Punt, JPEN Pierie, I Borel-Rinkes, ... JNCI: Journal of the National Cancer Institute 109 (9), djx015, 2017 | 636 | 2017 |
| KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience E Van Cutsem, I Lang, G D'haens, V Moiseyenko, J Zaluski, G Folprecht, ... Journal of Clinical Oncology 26 (15_suppl), 2-2, 2008 | 554 | 2008 |
| Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final … C Rödel, U Graeven, R Fietkau, W Hohenberger, T Hothorn, D Arnold, ... The Lancet Oncology 16 (8), 979-989, 2015 | 548 | 2015 |
| Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy N Halama, S Michel, M Kloor, I Zoernig, A Benner, A Spille, ... Cancer research 71 (17), 5670-5677, 2011 | 485 | 2011 |
| Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12 E Fokas, M Allgäuer, B Polat, G Klautke, GG Grabenbauer, R Fietkau, ... Journal of Clinical Oncology 37 (34), 3212-3222, 2019 | 461 | 2019 |
| Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for … SE Al-Batran, N Homann, H Schmalenberg, HG Kopp, GM Haag, ... Journal of Clinical Oncology 35 (15_suppl), 4004-4004, 2017 | 331 | 2017 |
| Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer J Taieb, K Le Malicot, Q Shi, F Penault-Llorca, O Bouché, J Tabernero, ... Journal of the National Cancer Institute 109 (5), djw272, 2017 | 318 | 2017 |
| Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial J Taieb, J Tabernero, E Mini, F Subtil, G Folprecht, JL Van Laethem, ... The Lancet Oncology 15 (8), 862-873, 2014 | 317 | 2014 |
| Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic … G Folprecht, MP Lutz, P Schöffski, T Seufferlein, A Nolting, P Pollert, ... Annals of Oncology 17 (3), 450-456, 2006 | 311 | 2006 |
| Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials G Folprecht, D Cunningham, P Ross, B Glimelius, F Di Costanzo, J Wils, ... Annals of Oncology 15 (9), 1330-1338, 2004 | 307 | 2004 |
| Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study) G Folprecht, T Gruenberger, W Bechstein, HR Raab, J Weitz, F Lordick, ... Annals of oncology 25 (5), 1018-1025, 2014 | 297 | 2014 |
| Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized … G Folprecht, MT Seymour, L Saltz, JY Douillard, H Hecker, RJ Stephens, ... Journal of Clinical Oncology 26 (9), 1443-1451, 2008 | 290 | 2008 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 261 | 2019 |
| Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final … C Rodel, U Graeven, R Fietkau, W Hohenberger, T Hothorn, D Arnold, ... Lancet Oncol 16 (8), 979-89, 2015 | 252 | 2015 |
